Inhale Gets Set For A Big Rush

Not many emerging biotechs have attracted as much attention in the past few years as Inhale Therapeutic Systems (INHL). Pfizer, Eli Lilly, and Baxter International have all invested millions in Inhale to develop a pulmonary device that would allow delivery of drugs through inhalation--including insulin for diabetic patients. The stock, which hit 37 1/4 last October, has dipped to 26 lately. But Inhale fans remain steadfast bulls.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.